Eli Lilly And Company

This study tests whether galcanezumab can prevent migraines in children aged 6 to 17 with episodic migraine. Over 500 participants receive either the drug or a placebo for 3 months. The main goal is to see if the drug reduces the number of migraine days each month.

This large Phase 3 trial tests a once-daily tablet called orforglipron against a placebo in 1,200 adults who are obese or overweight, some of whom also have type 2 diabetes. The study aims to see if the drug helps with weight loss and is safe. Participants are split into two grou…

This study tests a new daily injection called LY3549492 to help adults with obesity or overweight lose weight. About 288 participants will receive either the drug or a placebo for around one year. The main goal is to see how much weight they lose and how safe the treatment is.

This early-phase study tests a new drug called LY4101174 in people with advanced solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety, find the right dose, and see if it shri…

This study tests a drug called lebrikizumab in children aged 6 months to under 18 years with moderate-to-severe eczema. The goal is to see if it improves skin symptoms and reduces itching compared to a placebo. About 367 participants will receive either the drug or a placebo inje…

This study tests a drug called remternetug against a placebo in 1400 people with early Alzheimer's who are at risk for worsening memory and thinking problems. The goal is to see if the drug can delay or prevent further decline over up to 255 weeks. Participants who initially rece…

This study tests a drug called retatrutide in 643 adults with obesity to see if it helps them maintain weight loss over time. Everyone takes the drug for 80 weeks, then some switch to a placebo for 36 weeks. The goal is to find out if retatrutide can keep weight off better than n…

This study tests whether two drugs, bimagrumab and tirzepatide, can help adults with obesity or overweight lose weight safely. About 240 participants will receive one or both drugs or a placebo for 70 weeks. The main goal is to measure body weight change and fat loss.

This study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or colorectal can…

This study tested whether adding the drug abemaciclib to standard hormone therapy (fulvestrant) helps women with a common type of advanced breast cancer (HR+, HER2-) live longer without their cancer growing. About 669 women took part, and most received the combination. The goal w…

This study tests an experimental drug called LY3541860 in 35 adults with moderate-to-severe rheumatoid arthritis who did not get enough relief from at least one prior biologic or targeted therapy. The goal is to see if the drug reduces joint swelling, tenderness, and inflammation…

This early-phase study tests a new drug called LY3484356 in Chinese patients with a specific type of advanced breast cancer (ER+/HER2-). The main goal is to see how the drug moves through the body and how safe it is. Researchers will also check if the drug can shrink tumors. The …

This early-phase study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to find the safest dose and see if the drug can shrink tumors or slow the disease. About 193 participant…

This study tested a drug called abemaciclib against another drug, erlotinib, in people with stage IV lung cancer that has a specific KRAS gene change and has stopped responding to chemotherapy. The goal was to see if abemaciclib helps people live longer. About 450 adults took par…

This study tests an oral drug called selpercatinib for people with advanced solid tumors that have a specific RET gene change. The goal is to see if the drug is safe and can shrink tumors. About 857 adults with cancers like lung, thyroid, or colon cancer are taking part.

This study tests whether the drug ixekizumab is safe and works well for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years took part. The study compares ixekizumab to another dru…

This study was designed to test two drugs, bimagrumab and tirzepatide, alone or together, for weight loss in adults who are overweight or have obesity and also have type 2 diabetes. The goal was to see how well the drugs reduce body weight and improve health over about 13 months.…

This study compares tirzepatide, a newer diabetes medication, with other standard treatments for people recently diagnosed with type 2 diabetes (within the last 4 years). About 780 adults who are already taking metformin will be randomly assigned to receive either tirzepatide or …

This study tests whether the drug selpercatinib can delay the return of non-small cell lung cancer in people with early-stage disease (stages IB to IIIA) who have a specific RET gene change. Participants have already had surgery or radiation to remove or treat the cancer. About 1…

This study tests whether a targeted pill called selpercatinib works better than standard chemotherapy for people with a rare type of advanced lung cancer caused by a RET gene fusion. About 261 participants will receive either the study drug or standard treatment. The goal is to s…

This study tests an experimental drug called eltrekibart in 352 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and abscesses. The goal is to find the safest and most effective dose to reduce flare-ups and skin pain. Partic…

This study tests an experimental drug called mazdutide in 300 adults with alcohol use disorder. Participants receive either the drug or a placebo for several weeks to see if it reduces drinking behaviors. The goal is to find a new treatment option for people who struggle with alc…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like leukemia, lymphoma, or multiple myeloma) who have already tried standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or impro…

This study tests a once-daily tablet called orforglipron to see if it helps people with obesity or overweight lose weight. About 600 participants will take either the drug or a placebo for around 18 months. The main goal is to measure body weight changes and related health improv…

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue taking the drug. The goal is to see if it can keep…

This study tests whether adding the drug ramucirumab to standard chemotherapy can help children and young adults with a rare cancer called desmoplastic small round cell tumor (DSRCT) that has returned or not responded to prior treatment. About 30 participants will receive either …

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis drug (ixekizumab) helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 250 adults will receive either ixekizumab alone or both drugs together for up t…

This study tests an experimental drug called LY3871801 in 164 adults with moderate-to-severe rheumatoid arthritis (RA). Participants will receive either the drug or a placebo to see if it reduces joint pain and swelling. The goal is to find a new treatment option for people who h…

This study tests an oral drug called baricitinib in children aged 2 to 18 with active uveitis linked to juvenile idiopathic arthritis or a related antibody-positive condition. The goal is to see if the drug safely reduces eye inflammation. About 30 participants will receive baric…

This study tests a drug called lebrikizumab, given alone or with steroid creams, for people with moderate-to-severe eczema (atopic dermatitis). About 300 adults will receive the drug or a placebo for up to 62 weeks. The goal is to see if it safely reduces skin redness, itching, a…

This early-stage study tests a new medicine, LY3849891, in adults with fatty liver disease (MASLD) who have a specific gene change called PNPLA3 I148M. The main goals are to check the drug's safety and how well it works at reducing liver fat and inflammation. About 176 participan…

This study tests whether adding tirzepatide (a weight-loss drug) to ixekizumab (a standard arthritis treatment) helps people with psoriatic arthritis and obesity or overweight achieve better joint symptom relief and weight loss than ixekizumab alone. About 279 adults with active …

This study tests a daily pill called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with a specific RET gene change. The goal is to see if the drug shrinks tumors and how safe it is. Participants must have a RET alteration and measu…

This study tests a new weekly injection called retatrutide in people with type 2 diabetes and moderate to severe kidney disease who are already on insulin. The goal is to see if it helps lower blood sugar better than a placebo. About 320 adults will take part for around 14 months…

This study tests a once-daily oral medication called orforglipron to help adults with obesity or overweight who also have weight-related health conditions like high blood pressure or sleep apnea. Over 3,000 participants will take either the drug or a placebo for 72 weeks, with so…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already completed an earlier study and are still benefiting from the treatment. They…

This study tests whether adding the drug abemaciclib to standard chemotherapy can help children and young adults with Ewing's sarcoma that has returned or not responded to treatment. About 46 participants will receive either the drug combo or chemo alone. The goal is to see if th…

This study tests whether adding ramucirumab to the standard drug erlotinib helps people with a specific genetic type of advanced lung cancer (EGFR mutation-positive) live longer without their cancer growing. About 545 people who have not had prior treatment will receive either th…

This large Phase 3 study tests an investigational drug called lepodisiran in about 17,300 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either already have heart disease or are at high risk for a first heart attack or …

This study tests whether galcanezumab, a monthly injection, can safely reduce the number of migraine days in teenagers aged 12 to 17 who have chronic migraine (15+ headache days per month). Over 300 participants receive either the drug or a placebo for 3 months. The main goal is …

This program monitors 4,000 people with schizophrenia who receive the injectable medication Zyprexa Relprevv. The goal is to track and reduce the risk of a rare but serious side effect called post-injection delirium/sedation syndrome (PDSS). Researchers will record how often PDSS…

This study tests a radioactive drug called [Ac-225]-PSMA-62 in men with PSMA-positive prostate cancer that has spread. The goal is to find the safest and most effective dose, and to see if it can control the cancer. About 142 men with hormone-sensitive or castration-resistant pro…

This study tests whether adding the drug abemaciclib to standard chemotherapy (temozolomide) helps children and young adults with a fast-growing brain tumor called high-grade glioma. About 45 participants will receive either the combination or chemotherapy alone after radiation. …

This study tests whether different doses of the investigational drug tirzepatide can help people with type 2 diabetes and obesity lose weight and improve blood sugar control. About 414 adults who are already taking metformin will receive either tirzepatide or a placebo for up to …

This study tests whether mirikizumab can reduce the sudden, urgent need to use the bathroom in adults with moderate to severe ulcerative colitis. About 172 participants will receive the drug and report their urgency levels over 36 weeks. The goal is to see if the drug improves th…

This study tests a drug called lebrikizumab for people with moderate-to-severe eczema on their hands and feet. About 206 adults and teens will receive either the drug or a placebo for 16 weeks to see if it clears skin and reduces itching. The goal is to find a better treatment op…

This study tests an experimental drug (LY3848575) to see if it safely reduces chronic nerve pain starting in the feet and moving up the legs. About 558 adults with this type of pain will receive either the drug or a placebo for up to 30 weeks. The goal is to find the best dose th…

This study looks at how well three different tablet versions of the drug LY4100511 are absorbed by the body in 48 healthy adults. It also checks if taking a common stomach acid medication (a proton pump inhibitor) changes absorption. The goal is to find the best tablet form for f…

This early-stage study tests a new drug, LY4005130, in 118 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, given as a shot under the skin or into a vein. The study tracks side effects and measures drug levels i…

This early-stage study looks at how a new drug called LY3537031 enters the bloodstream and how long it stays in the body. It involves 46 healthy adults who receive the drug either under the skin in different areas or into a vein. The goal is to understand the drug's behavior and …

This early-stage study tests whether a single dose of remternetug is safe in 24 healthy Chinese adults. Participants receive the drug under the skin and are monitored for side effects and how the drug moves through the body. The study lasts up to 25 weeks and does not aim to trea…

This study looks at how fasting and temporarily stopping the diabetes drug dulaglutide affect what stays in the stomach after a meal. About 20 people with type 2 diabetes will have their stomachs checked with ultrasound after eating. The goal is to understand how these factors in…